GlassScriptPhysician profile
Faryal U Baloch
NPI 1174519847
$5,746.84
in general payments reported to CMS, 2019-2025
29 companies · $781 in 2025
The $781 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $735 · 2021: $1,180 · 2022: $1,003 · 2023: $749 · 2024: $921 · 2025: $781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,393 · Education: $57.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,392.99 |
| Education | $57.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,402.52 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Amgen INC. | $597.89 | 2019-2024 | Enbrel |
| Janssen Biotech, INC. | $387.73 | 2021-2025 | Tremfya, Simponi Aria |
| Pfizer INC. | $377.99 | 2019-2025 | |
| Ucb, INC. | $281.98 | 2020-2025 | Cimzia, Bimzelx |
| Aurinia Pharma U.S., INC. | $218.23 | 2021-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $187.12 | 2020-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.50 | 2021-2022 | |
| Lilly USA, LLC | $157.24 | 2019-2025 | Mounjaro, Zepbound |
| Sobi, INC | $149.18 | 2022-2024 | |
| Glaxosmithkline, LLC. | $137.52 | 2020-2025 | Benlysta |
| Horizon Therapeutics Plc | $125.97 | 2019-2022 | |
| Novo Nordisk INC | $102.13 | 2020-2024 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $46.66 | 2025 | Lokelma |
| Abbott Laboratories | $46.12 | 2022-2023 | Freestyle Libre 2 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $43.92 | 2023-2024 | Dexcom G6 Transmitter |
| Genzyme Corporation | $37.46 | 2023 | |
| Mallinckrodt Hospital Products INC. | $36.32 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $35.00 | 2024-2025 | Orencia |
| Exact Sciences Corporation | $32.86 | 2024-2025 | Cologuard Collection Kit |
| Radius Health, INC. | $32.14 | 2023 | Tymlos |
| Alexion Pharmaceuticals, INC. | $22.89 | 2025 | Strensiq |
| Sandoz INC. | $21.34 | 2024 | Hyrimoz |
| Octapharma USA, INC. | $21.17 | 2025 | Octagam Immune Globulin (Human) |
| Xeris Pharmaceuticals, INC. | $17.84 | 2021 | |
| Organon LLC | $17.73 | 2023-2024 | Renflexis |
| Amarin Pharma, INC. | $15.59 | 2020 | |
| Currax Pharmaceuticals LLC | $14.47 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $13.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faryal Baloch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.